Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T22:13:43.981Z.
Calculation as of: 2026-10-06T22:13:43.981Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 667dd3b64d3a271f66e92979ae52668ccbc7e2b5b2cdee7c8377401ac3ef4785
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Tectonic Therapeutic, Inc.
Market Cap
$422.86M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$419.87M
Price/FCF Ratio
N/A
TTM Avg
44.26
3Y Avg
44.26
5Y Avg
44.26
Market Cap
$426.51M
Price/FCF Ratio
N/A
TTM Avg
102.37
3Y Avg
102.37
5Y Avg
102.37
Market Cap
$418.95M
Price/FCF Ratio
N/A
TTM Avg
53.84
3Y Avg
53.84
5Y Avg
53.84
Market Cap
$416.27M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | $422.86M | N/A | N/A | N/A | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | N/A | 53.25 | 37.33 | 28.89 |
| Prothena Corporation plc (PRTA)vs › | $419.87M | N/A | 44.26 | 44.26 | 44.26 |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | N/A | 102.37 | 102.37 | 102.37 |
| Editas Medicine, Inc. (EDIT)vs › | $418.95M | N/A | 53.84 | 53.84 | 53.84 |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | N/A | N/A | N/A | N/A |
| Rezolute, Inc. (RZLT)vs › | $415.98M | N/A | N/A | N/A | N/A |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | N/A | N/A | N/A | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
